Agios Pharmaceuticals, Inc. Forecast, price target & analysts
Agios Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Agios Pharmaceuticals, Inc. Classifications & Recommendation:
Agios Pharmaceuticals, Inc. Price Target
| Target Price | $53.17 |
| Price | $29.10 |
| Potential |
82.73%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Agios Pharmaceuticals, Inc. 2026 .
The average Agios Pharmaceuticals, Inc. target price is $53.17.
This is
82.73%
register free of charge
$74.00
154.30%
register free of charge
$38.22
31.34%
register free of charge
|
|
| A rating was issued by 9 analysts: 6 Analysts recommend Agios Pharmaceuticals, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Agios Pharmaceuticals, Inc. stock has an average upside potential 2026 of
82.73%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 36.50 | 49.88 |
| 36.09% | 36.65% | |
| EBITDA Margin | -1,150.90% | -983.83% |
| 19.80% | 14.52% | |
| Net Margin | 1,822.86% | -860.17% |
| 235.12% | 147.19% |
9 Analysts have issued a sales forecast Agios Pharmaceuticals, Inc. 2025 . The average Agios Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Agios Pharmaceuticals, Inc. EBITDA forecast 2025. The average Agios Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Agios Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Agios Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 11.64 | -7.51 |
| 283.89% | 164.52% | |
| P/E | negative | |
| EV/Sales | 16.65 |
5 Analysts have issued a Agios Pharmaceuticals, Inc. forecast for earnings per share. The average Agios Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Agios Pharmaceuticals, Inc....
Current Agios Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Dec 18 2024 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Dec 10 2024 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Dec 09 2024 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Nov 01 2024 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Nov 01 2024 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Oct 16 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 24 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Dec 18 2024 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Dec 10 2024 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Dec 09 2024 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Nov 01 2024 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Nov 01 2024 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Oct 16 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
